Seven Fleet Capital Management LP Buys Shares of 240,963 OnKure Therapeutics, Inc. $OKUR

Seven Fleet Capital Management LP purchased a new position in OnKure Therapeutics, Inc. (NASDAQ:OKUR) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 240,963 shares of the company’s stock, valued at approximately $1,099,000. Seven Fleet Capital Management LP owned approximately 0.60% of OnKure Therapeutics at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. XTX Topco Ltd acquired a new stake in OnKure Therapeutics in the 2nd quarter valued at $25,000. Jane Street Group LLC bought a new position in OnKure Therapeutics in the fourth quarter valued at approximately $56,000. Hsbc Holdings PLC acquired a new position in shares of OnKure Therapeutics during the 4th quarter worth approximately $58,000. Rangeley Capital LLC bought a new stake in shares of OnKure Therapeutics during the 2nd quarter worth approximately $71,000. Finally, Barclays PLC boosted its holdings in shares of OnKure Therapeutics by 4,286.8% in the 4th quarter. Barclays PLC now owns 27,242 shares of the company’s stock valued at $79,000 after buying an additional 26,621 shares during the last quarter. Institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Stock Up 0.6%

Shares of OnKure Therapeutics stock opened at $3.58 on Friday. The stock has a market capitalization of $144.63 million, a price-to-earnings ratio of -1.02 and a beta of 0.23. OnKure Therapeutics, Inc. has a twelve month low of $2.23 and a twelve month high of $5.38. The company has a 50-day simple moving average of $4.09 and a two-hundred day simple moving average of $4.00.

OnKure Therapeutics (NASDAQ:OKUR) last announced its earnings results on Tuesday, August 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.23. On average, sell-side analysts anticipate that OnKure Therapeutics, Inc. will post -1.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

OKUR has been the subject of a number of analyst reports. Wall Street Zen raised shares of OnKure Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Oppenheimer reissued an “outperform” rating and set a $14.00 price target on shares of OnKure Therapeutics in a research report on Friday, August 14th. Weiss Ratings cut OnKure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. Finally, HC Wainwright reduced their target price on OnKure Therapeutics to $21.00 and set a “buy” rating for the company in a research note on Monday, July 20th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $17.50.

OnKure Therapeutics Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.